Literature DB >> 23023055

Taking a break from huntingtin.

Beverly L Davidson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23023055      PMCID： PMC3464649          DOI： 10.1038/mt.2012.191

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  14 in total

1.  Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease.

Authors:  A Yamamoto; J J Lucas; R Hen
Journal:  Cell       Date:  2000-03-31       Impact factor: 41.582

2.  Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.

Authors:  Holly B Kordasiewicz; Lisa M Stanek; Edward V Wancewicz; Curt Mazur; Melissa M McAlonis; Kimberly A Pytel; Jonathan W Artates; Andreas Weiss; Seng H Cheng; Lamya S Shihabuddin; Gene Hung; C Frank Bennett; Don W Cleveland
Journal:  Neuron       Date:  2012-06-21       Impact factor: 17.173

3.  RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model.

Authors:  Scott Q Harper; Patrick D Staber; Xiaohua He; Steven L Eliason; Inês H Martins; Qinwen Mao; Linda Yang; Robert M Kotin; Henry L Paulson; Beverly L Davidson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-05       Impact factor: 11.205

4.  Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression.

Authors:  Dongbo Yu; Hannah Pendergraff; Jing Liu; Holly B Kordasiewicz; Don W Cleveland; Eric E Swayze; Walt F Lima; Stanley T Crooke; Thazha P Prakash; David R Corey
Journal:  Cell       Date:  2012-08-31       Impact factor: 41.582

5.  Singles engage the RNA interference pathway.

Authors:  Beverly L Davidson; Alex Mas Monteys
Journal:  Cell       Date:  2012-08-31       Impact factor: 41.582

6.  Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice.

Authors:  Edgardo Rodriguez-Lebron; Eileen M Denovan-Wright; Kevin Nash; Alfred S Lewin; Ronald J Mandel
Journal:  Mol Ther       Date:  2005-10       Impact factor: 11.454

Review 7.  Milestones in huntington disease.

Authors:  Ira Shoulson; Anne B Young
Journal:  Mov Disord       Date:  2011-05       Impact factor: 10.338

8.  Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease.

Authors:  Miguel Díaz-Hernández; Jesús Torres-Peraza; Alejandro Salvatori-Abarca; María A Morán; Pilar Gómez-Ramos; Jordi Alberch; José J Lucas
Journal:  J Neurosci       Date:  2005-10-19       Impact factor: 6.167

9.  Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.

Authors:  Ryan L Boudreau; Jodi L McBride; Inês Martins; Shihao Shen; Yi Xing; Barrie J Carter; Beverly L Davidson
Journal:  Mol Ther       Date:  2009-02-24       Impact factor: 11.454

10.  Sustained effects of nonallele-specific Huntingtin silencing.

Authors:  Valérie Drouet; Valérie Perrin; Raymonde Hassig; Noëlle Dufour; Gwennaelle Auregan; Sandro Alves; Gilles Bonvento; Emmanuel Brouillet; Ruth Luthi-Carter; Philippe Hantraye; Nicole Déglon
Journal:  Ann Neurol       Date:  2009-03       Impact factor: 10.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.